PMID- 36588742
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230103
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - Pharmacist-led olaparib follow-up service for ambulatory ovarian cancer patients: 
      A prospective study in a tertiary specialized cancer hospital in China.
PG  - 1037726
LID - 10.3389/fphar.2022.1037726 [doi]
LID - 1037726
AB  - Purpose: To establish a pharmacist-led olaparib follow-up program for ovarian 
      cancer patients, provide patient education, get information on adverse drug 
      reactions (ADRs), and identify and manage drug-related problems. Methods: 
      Ambulatory adult patients with ovarian cancer receiving olaparib were enrolled. 
      At least one follow-up session was conducted by clinical pharmacists. Pharmacists 
      collected data on the type and grade of ADRs, drug adherence, olaparib dosing, 
      concomitant medications, and pharmacists' suggestions. Results: 83 patients were 
      enrolled with the median age of 58. The average number of the follow-up sessions 
      provided to each patient was 1.31, and the average duration of each follow-up was 
      17.78 min. The olaparib starting dose for most patients (97.59%) was 600 mg/d. 
      36.14% of the patients had missed olaparib doses and 27.71% of the patients had 
      dose adjustments due to ADRs. The most common ADRs (incidence>/=10%) were: fatigue 
      (40.96%), anemia (36.14%), leukopenia (36.14%), nausea (28.92%), thrombocytopenia 
      (16.87%), anorexia (16.87%), dyspepsia (15.66%). The tolerability profiles were 
      generally similar between patients treated for "first-line maintenance" and those 
      treated for "recurrence maintenance" (p > .05). There were 42% of the patients 
      who were concomitantly taking medications without exact chemical contents (such 
      as formulated Chinese medicines and Chinese decoctions), and common types of 
      concomitant medications with exact drug names were antihypertensive, 
      anti-hyperglycemic, and anti-hyperlipidemic medications. The pharmacists 
      identified 4 clinically significant drug-drug interactions (DDIs) in two 
      patients. Pharmacists made 196 suggestions mainly related to rational use of the 
      medications and management of ADRs. Conclusion: The study provides the first 
      report about pharmacist-led follow-up service for olaparib. The types of ADRs 
      were similar to those previously observed in clinical trials, and the profiles of 
      ADRs in different types of patients (first-line maintenance vs. recurrence 
      maintenance) were also similar. Pharmacists identified drug-related problems 
      (such as adherence, DDIs and management of ADRs) and offer suggestions for the 
      patients.
CI  - Copyright (c) 2022 Wang, Du, Yang, Lau, Dai, Qin, Li and Li.
FAU - Wang, Yanting
AU  - Wang Y
AD  - Department of Pharmacy, National Cancer Center/National Clinical Research Center 
      for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, China.
FAU - Du, Di
AU  - Du D
AD  - Department of Pharmacy, National Cancer Center/National Clinical Research Center 
      for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, China.
AD  - Pharmaceutical Department, Hubei Cancer Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, Hubei, China.
FAU - Yang, Jun
AU  - Yang J
AD  - Department of Pharmacy, National Cancer Center/National Clinical Research Center 
      for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, China.
FAU - Lau, Alan H
AU  - Lau AH
AD  - Department of Pharmacy Practice, College of Pharmacy, University of Illinois at 
      Chicago, Chicago, IL, United States.
FAU - Dai, Yuanyuan
AU  - Dai Y
AD  - Department of Pharmacy, National Cancer Center/National Clinical Research Center 
      for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, China.
AD  - National Cancer Center/National Clinical Research Center for Cancer/Hebei Cancer 
      Hospital, Chinese Academy of Medical Sciences, Langfang, China.
FAU - Qin, Wangjun
AU  - Qin W
AD  - Department of Pharmacy, China-Japan Friendship Hospital, Beijing, China.
FAU - Li, Ning
AU  - Li N
AD  - Department of Gynecologic Oncology, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, China.
FAU - Li, Guohui
AU  - Li G
AD  - Department of Pharmacy, National Cancer Center/National Clinical Research Center 
      for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20221213
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9795018
OTO - NOTNLM
OT  - adverse drug reactions
OT  - drug adherence
OT  - drug-drug interaction
OT  - follow-up
OT  - olaparib
OT  - ovarian cancer
OT  - pharmacist
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/01/03 06:00
MHDA- 2023/01/03 06:01
PMCR- 2022/12/13
CRDT- 2023/01/02 03:40
PHST- 2022/09/06 00:00 [received]
PHST- 2022/11/30 00:00 [accepted]
PHST- 2023/01/02 03:40 [entrez]
PHST- 2023/01/03 06:00 [pubmed]
PHST- 2023/01/03 06:01 [medline]
PHST- 2022/12/13 00:00 [pmc-release]
AID - 1037726 [pii]
AID - 10.3389/fphar.2022.1037726 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Dec 13;13:1037726. doi: 10.3389/fphar.2022.1037726. 
      eCollection 2022.